297 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
AZN Astrazeneca PLC $36.13 $91.53B Sell
Article Searches
Can Nektar Therapeutics Disrupt This $20 Billion Market? https://www.fool.com/investing/2018/05/31/can-nektar-therapeutics-disrupt-this-20-billion-ma.aspx?source=iedfolrf0000001 May 31, 2018 - This company hopes to profit from shaking up how doctors treat lower back pain.
AstraZeneca (AZN) Stock on Growth Path This Year: Here's Why http://www.zacks.com/stock/news/305601/astrazeneca-azn-stock-on-growth-path-this-year-heres-why?cid=CS-ZC-FT-305601 May 30, 2018 - AstraZeneca's (AZN) stock is up this year while the Large-Cap Pharma industry is witnessing a decline
Clovis' Rubraca Gets Approval in Europe for Ovarian Cancer http://www.zacks.com/stock/news/305627/clovis-rubraca-gets-approval-in-europe-for-ovarian-cancer?cid=CS-ZC-FT-305627 May 30, 2018 - Clovis Oncology's (CLVS) PARP inhibitor, Rubraca, gets its first approval in Europe for the treatment of BRCA-mutant ovarian cancer in third- or later-line setting.
Novo Nordisk's Oral Ozempic Positive in Diabetes Study http://www.zacks.com/stock/news/305565/novo-nordisks-oral-ozempic-positive-in-diabetes-study?cid=CS-ZC-FT-305565 May 30, 2018 - Novo Nordisk's (NVO) oral formulation of Ozempic acts better in lowering blood sugar levels in adults with type II diabetes than Eli Lilly's Jardiance, in the second phase IIIa study, PIONEER 2.
AstraZeneca's Imfinzi Improves Survival in Lung Cancer Study http://www.zacks.com/stock/news/305320/astrazenecas-imfinzi-improves-survival-in-lung-cancer-study?cid=CS-ZC-FT-305320 May 28, 2018 - AstraZeneca Plc. (AZN) announces positive overall survival (OS) data from an interim analysis of a phase III PACIFIC study evaluating its oncology candidate, Imfinzi.
Stocks making the biggest moves premarket: FL, HIBB, BKE, GPS, DECK, ADSK, ROST, AZN & more https://www.cnbc.com/2018/05/25/stocks-making-the-biggest-moves-premarket-fl-hibb-bke-gps-deck-adsk-rost-more.html May 25, 2018 - Names on the move ahead of the open.
Is This Stock the Next Biotech Acquisition Target? https://www.fool.com/investing/2018/05/22/is-this-stock-the-next-biotech-acquisition-target.aspx?source=iedfolrf0000001 May 22, 2018 - Optimism is growing that this cancer drug developer will be the next biotech to be acquired.
Inovio Initiates Phase II Study on Pipeline Drug VGX-3100 http://www.zacks.com/stock/news/304524/inovio-initiates-phase-ii-study-on-pipeline-drug-vgx-3100?cid=CS-ZC-FT-304524 May 22, 2018 - Inovio (INO) begins a phase II study to evaluate the efficacy of its pipeline candidate VGX-3100 on adult men and women with human papilloma virus (HPV)-related anal dysplasia.
AstraZeneca's Lokelma Gains FDA Nod to Treat Hyperkalemia http://www.zacks.com/stock/news/304359/astrazenecas-lokelma-gains-fda-nod-to-treat-hyperkalemia?cid=CS-ZC-FT-304359 May 21, 2018 - AstraZeneca's (AZN) Lokelma secures an FDA approval for the treatment of hyperkalemia in adults.
AstraZeneca's (AZN) CEO Pascal Soriot on Q1 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4175600-astrazenecas-azn-ceo-pascal-soriot-q1-2018-results-earnings-call-transcript?source=feed_sector_healthcare May 18, 2018 - AstraZeneca PLC (NYSE:AZN) Q1 2018 Results Earnings Conference Call May 18, 2018 07:00 AM ET Executives Pascal Soriot - CEO Dave Fredrickson - EVP, Oncology Business Unit Mark Mallon - EVP, GPPS, GMA

Pages: 123456...30

Page 1>